149 related articles for article (PubMed ID: 12200393)
1. Prolongation of cardiac repolarization by arsenic trioxide.
Chiang CE; Luk HN; Wang TM; Ding PY
Blood; 2002 Sep; 100(6):2249-52. PubMed ID: 12200393
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Raghu KG; Yadav GK; Singh R; Prathapan A; Sharma S; Bhadauria S
J Environ Pathol Toxicol Oncol; 2009; 28(3):241-52. PubMed ID: 19888912
[TBL] [Abstract][Full Text] [Related]
4. Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time.
Lu HR; Vlaminckx E; Cools F; Gallacher DJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):135-44. PubMed ID: 22445855
[TBL] [Abstract][Full Text] [Related]
5. Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Sun HL; Chu WF; Dong DL; Liu Y; Bai YL; Wang XH; Zhou J; Yang BF
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):381-8. PubMed ID: 16623862
[TBL] [Abstract][Full Text] [Related]
6. Cardiac monitoring of patients receiving arsenic trioxide therapy.
Unnikrishnan D; Dutcher JP; Garl S; Varshneya N; Lucariello R; Wiernik PH
Br J Haematol; 2004 Mar; 124(5):610-7. PubMed ID: 14871247
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Roboz GJ; Ritchie EK; Carlin RF; Samuel M; Gale L; Provenzano-Gober JL; Curcio TJ; Feldman EJ; Kligfield PD
J Clin Oncol; 2014 Nov; 32(33):3723-8. PubMed ID: 25245447
[TBL] [Abstract][Full Text] [Related]
8. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
[TBL] [Abstract][Full Text] [Related]
9. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and olanzapine co-administration: case analysis.
Kaufman KR; Chhabra S; Levitt M; Sood R
J Oncol Pharm Pract; 2011 Sep; 17(3):260-4. PubMed ID: 20015926
[TBL] [Abstract][Full Text] [Related]
11. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
12. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
15. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
[TBL] [Abstract][Full Text] [Related]
16. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
17. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
Zhou J; Meng R; Liu Y; Wang W; Li BX; Yang BF
Zhonghua Xue Ye Xue Za Zhi; 2004 Jan; 25(1):31-4. PubMed ID: 14990074
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
Zhao S; Zhang X; Zhang J; Zhang J; Zou H; Liu Y; Dong X; Sun X
J Chemother; 2008 Apr; 20(2):253-62. PubMed ID: 18467254
[TBL] [Abstract][Full Text] [Related]
20. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Chu W; Li C; Qu X; Zhao D; Wang X; Yu X; Cai F; Liang H; Zhang Y; Zhao X; Li B; Qiao G; Dong D; Lu Y; Du Z; Yang B
Cardiovasc Res; 2012 Oct; 96(1):90-8. PubMed ID: 22853924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
